Development of an Injectable Slow-Release Metformin Formulation and Evaluation of Its Potential Antitumor Effects

Sara Baldassari, Agnese Solari, Guendalina Zuccari, Giuliana Drava, Sara Pastorino, Carmen Fucile, Valeria Marini, Antonio Daga, Alessandra Pattarozzi, Alessandra Ratto, Angelo Ferrari, Francesca Mattioli, Federica Barbieri, Gabriele Caviglioli, Tullio Florio

Research output: Contribution to journalArticlepeer-review


Metformin is an antidiabetic drug which possesses antiproliferative activity in cancer cells when administered at high doses, due to its unfavorable pharmacokinetics. The aim of this work was to develop a pharmacological tool for the release of metformin in proximity of the tumor, allowing high local concentrations, and to demonstrate the in vivo antitumor efficacy after a prolonged metformin exposition. A 1.2% w/w metformin thermoresponsive parenteral formulation based on poloxamers P407 and P124, injectable at room temperature and undergoing a sol-gel transition at body temperature, has been developed and optimized for rheological, thermal and release control properties; the formulation is easily scalable, and proved to be stable during a 1-month storage at 5 °C. Using NOD/SCID mice pseudo-orthotopically grafted with MDA-MB-231/luc+ human breast cancer cells, we report that multiple administrations of 100 mg of the optimized metformin formulation close to the tumor site cause tissue accumulation of the drug at levels significantly higher than those observed in plasma, and enough to exert antiproliferative and pro-apoptotic activities. Our results demonstrate that this formulation is endowed with good stability, tolerability, thermal and rheological properties, representing a novel tool to be pursued in further investigations for adjuvant cancer treatment.

Original languageEnglish
Article number3929
JournalScientific Reports
Issue number1
Publication statusPublished - Dec 1 2018

ASJC Scopus subject areas

  • General


Dive into the research topics of 'Development of an Injectable Slow-Release Metformin Formulation and Evaluation of Its Potential Antitumor Effects'. Together they form a unique fingerprint.

Cite this